Pathologic Myopia
8
2
2
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia
High-throughput Large-model-based AI-assisted Diagnosis Using OCT
Follow up of High Myopic Eyes
Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia
Brolucizumab for CNV Associated With Pathologic Myopia
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)
Shanghai Child and Adolescent Large-scale Eye Study -High Myopia Registration